IMM 124E

Drug Profile

IMM 124E

Alternative Names: Anti-LPS colostrum (Imm124-E) - Immuron; Bovine colostrum; Hyper-immune bovine colostrum powder (BCP) for NASH - Immuron; IMM-124E; IMM122-I

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Immuron
  • Developer Emory University; Hadassah Medical Organization; Immuron; La Trobe University; University of Melbourne; University of Zurich; Virginia Commonwealth University
  • Class Antibodies; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholic hepatitis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Autistic disorder; Gastroenteritis
  • No development reported Metabolic syndrome

Most Recent Events

  • 10 Jul 2017 Interim efficacy and adverse event data from a phase II trial in Non-alcoholic steatohepatitis released by Immuron
  • 18 Apr 2017 Preclinical trials in Gastroenteritis (Colitis) in Switzerland (unspecified route) before April 2017
  • 20 Feb 2017 Immuron completes enrolment in its phase II trial for non-alcoholic steatohepatitis in USA, Australia and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top